Fulvestrant ('Faslodex') is a new drug for curing breast cancer which was deve-loped by Astrazeneca Company. In2002, the US Food and Drug Administration (FD-A)granted approval for fulvestrant. Since March2004, fulvestrant has also been lice-nsed in the European Union. It is a new type of estrogen receptor antagonist, and is us-ed for the treatment of hormone receptor-positive advanced breast cancer in postmeno-pausal women with disease progression following antiestrogen therapy. In order toimprove the synth...